IP Library Granted Patent US 10,391,064
Granted Patent B2
US 10,391,064 · App. 15/600,085 · Granted Aug 27, 2019

Microbiota restoration therapy (MRT) compositions and methods of manufacture

Inventors: Lee A. Jones (Fridley, MN); Courtney R. Jones (Fridley, MN); Beth Anne-Szkudlarek Brown (Plymouth, MN); Joshua Erickson (Champlin, MN)
Assignee: REBIOTIX, INC.
A61K9/4833A61K9/19A61K9/4858A61K9/4866A61K35/74A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,391,064
App. No.
15/600,085
Granted
Aug 27, 2019
Kind
B2
Abstract

Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.

Claims (21)

1. A microbiota restoration therapy composition for oral delivery, comprising:

a processed human fecal preparation encapsulated in one or more capsules;

wherein the processed human fecal preparation is manufactured by:

collecting a fresh human fecal sample;

adding a diluent to the fresh human fecal sample to form a diluted sample;

wherein the diluent includes 30-90 g/L polyethylene glycol in saline;

mixing the diluted sample with a mixing apparatus;

filtering the mixture;

transferring a filtrate from the filtering step to a centrifuge tube;

centrifuging the filtrate to arrive at the purified intermediate;

lyophilizing the purified intermediate to form a plurality of lyophilized pellets; and

encapsulating the plurality of lyophilized pellets in the one or more capsules.

2. The microbiota restoration therapy composition of claim 1 , wherein the processed human fecal preparation comprises spore forming bacteria.

3. The microbiota restoration therapy composition of claim 1 , wherein the processed human fecal preparation consists essentially of spore forming bacteria.

4. The microbiota restoration therapy composition of claim 1 , wherein the processed human fecal preparation is free from non-spore forming bacteria.

5. The microbiota restoration therapy composition of claim 1 , wherein the processed human fecal preparation comprises non-spore forming bacteria.

6. The microbiota restoration therapy composition of claim 1 , wherein the processed human fecal preparation consists essentially of non-spore forming bacteria.

7. The microbiota restoration therapy composition of claim 1 , wherein the processed human fecal preparation is free from spore forming bacteria.

8. The microbiota restoration therapy composition of claim 1 , wherein the one or more capsules comprise hypromellose capsule.

9. The microbiota restoration therapy composition of claim 1 , further comprising banding the capsules.

10. The microbiota restoration therapy composition of claim 9 , wherein the banding material comprises hypromellose, an anionic copolymer based on methacrylic acid and methyl methacrylate, hypromellose phthalate, hypromellose acetate succinate, or combinations thereof.

Assignments (1)
CHANGE OF NAME Recorded Jan 27, 2025
From: REBIOTIX INC.
To: FERRING MICROBIOME INC.
Reel/Frame 070022/0505 →
Continuity (4)
Continuation 15178176 · Jun 9, 2016
Provisional Application 62247825 · Oct 29, 2015
Provisional Application 62173182 · Jun 9, 2015
Related Publication 20170252303A1 · Sep 7, 2017
Cited By (2)
US 12,303,537 US 12,364,721